Trials / Completed
CompletedNCT02098473
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effective dose(s) of RPC4046 in the treatment of Eosinophilic Esophagitis (EoE). This trial consists of two phases: 16 weeks of double-blind treatment and 52 weeks of open-label extension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RPC4046 | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-08-31
- Primary completion
- 2016-02-17
- Completion
- 2017-01-30
- First posted
- 2014-03-28
- Last updated
- 2017-05-09
Locations
30 sites across 3 countries: United States, Canada, Switzerland
Source: ClinicalTrials.gov record NCT02098473. Inclusion in this directory is not an endorsement.